Chronic Pain, Central Sensitization, tapentadol, pregabalin
Conditions
Interventions
- Tapentadol:
Dose: start dose of 50mg 2x/day, increase by 50mg 2x/day every 3 days until sufficient analgesia is reached with tolerable adverse effects. Max 500 mg/day.
Route: Oral administration
Sponsors
University Medical Center Groningen, dept of Anesthesiology
Eligibility
Inclusion criteria
Inclusion criteria: - Gender: female - Age of patients (18-65 years old) - Presence of proven endometriosis or CLBPr - Signs of central sensitization - No contraindications for opioids or pregabalin. - Signed informed consent.
Exclusion criteria
Exclusion criteria: - No or insufficient understanding of Dutch language. - Incapacity to follow instructions. - Mental incompetence to provide informed consent. - CLBP with radiation to both legs. - Pain in the lower leg or at the deltoid muscle (sites for the QST measurement will be applied) - Usage of opioids with more powerful spectre, such as oxycodone, fentanyl, morphine in the two weeks prior to start of the study. - Previous usage of pregabalin or tapentadol - Alcohol abuse. - Pregnancy or woman who wish to be pregnant.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Central Sensitzation parameters - pressure pain threshold (PPT) - pressure pain tolerance threshold (PTT) - conditioned pain modulation (CPM) - size of allodynia - Wind-up ratio (WUR) - Central Sensitization Inventory (CSI) | — |
Secondary
| Measure | Time frame |
|---|---|
| - Visual Analog Scale (VAS) - Pain Disability Index (PDI) - Pain Catastrophizing Scale (PCS) - Pain Vigilance and Awareness Questionnaire (PVAQ) - Adverse effects of the medications - Dosages of the medication during the treatment period | — |
Contacts
Public ContactR. Spanjersberg
Hanzeplein 1
Outcome results
None listed